Gilead Sciences Inc (GILD.OQ)
52.23USD
4:00pm EDT
$0.57 (+1.11%)
$51.65
$51.70
$52.67
$51.42
3,465,237
3,630,019
$58.06
$24.80
GILD.OQ
About
Overall
| Beta: | 0.51 |
| Market Cap (Mil.): | $78,792.26 |
| Shares Outstanding (Mil.): | 1,525.36 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| GILD.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 34.27 | 34.45 | 32.18 |
| EPS (TTM): | 1.51 | -- | -- |
| ROI: | 17.09 | -2.81 | 18.91 |
| ROE: | 32.88 | -3.51 | 19.87 |
FDA grants priority review status to Gilead's hepatitis C drug
June 7 - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.
Experimental Gilead drug effective in early-stage leukemia trial
- An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV medications.
Experimental Gilead drug effective in early-stage leukemia trial
May 15 - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV medications.
Gilead profit rises, but sales of older HIV drugs dip
- Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.
UPDATE 2-Gilead profit rises, but sales of older HIV drugs dip
May 2 - Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.
CORRECTED-Gilead profit rises 63 pct, sales of older HIV drugs dip
(Corrects 3rd paragraph to show Complera sales rose 184 percent, not 10 percent; shows that sales of Stribild totaled $92.1 million, with no prior year comparison, not that they rose 184 percent)
Gilead profit rises 63 percent, sales of older HIV drugs dip
- Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by higher sales of new products, but the results fell slightly short of Wall Street estimates.
Gilead combo hepatitis C pill effective in small trial
- Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either eight weeks or 12 weeks of treatment in a small mid-stage study.
UPDATE 2-Gilead combo hepatitis C pill effective in small trial
(Adds competitive details, analyst comment, updates shares)
Gilead combo hepatitis C pill shown effective in small trial
May 2 - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $27.70 | -0.08 |
| Novartis AG (NOVN.VX) | CHF67.45 | +0.15 |
| Merck & Co., Inc. (MRK.N) | $46.55 | +0.23 |
| Roche Holding Ltd. (ROG.VX) | CHF235.70 | +1.10 |
| Abbott Laboratories (ABT.N) | $34.86 | -0.17 |
| AstraZeneca plc (AZN.L) | 3,173.00p | +22.00 |
| GlaxoSmithKline plc (GSK.L) | 1,670.00p | +11.50 |
| Bristol Myers Squibb Co. (BMY.N) | $43.99 | -0.48 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
| Shire PLC (SHP.L) | 2,121.00p | +33.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
